Economic assessment of eltrombopag in the treatment of thrombocytopenia

References

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
   PubMed Web of Science ®Google Scholar
• Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity and mortality. BMC Public Health 2009;9:34
   PubMed Web of Science ®Google Scholar
• ECDC Technical report. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies 2010
   Google Scholar
• Libro Bianco AISF 2011. Proposta per un piano nazionale per il controllo delle malattie epatiche
   Google Scholar
• Mariano A, Scalia Tomba G, Tosti ME, et al. Estimating the incidence, prevalence and clinica’ burden of hepatitis C over time in Italy. Scandi Infect Dis 2009;41:689-99
   PubMed Web of Science ®Google Scholar
• Guadagnino V, Stroffolini T, Caroleo B, et al. Sersale’s Study Group. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection. Dig Liver Dis 2013;45(5):403-7
   PubMedGoogle Scholar
• Giannini EG, Marenco S, Fazio V, et al. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int 2012;32:7
   Google Scholar
• Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2013;146(2):442-52.e1
   Google Scholar
• Boyers D, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics 2012;30(6):483-95
   PubMed Web of Science ®Google Scholar
• Boyers D, Jia X, Crowther M, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Health Technol Assess 2011;15(Suppl 1):23-32
   Google Scholar
• AIFA, Boceprevir (Determina n. 714/2012 - GU n. 287 del 10-12-2012)
   Google Scholar
• AIFA, Telaprevir (Determina n. 713/2012 - GU n. 287 del 10-12-2012)
   Google Scholar
• Dienstag JL, Ghany MG, Morgan TR, et al. HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54(2):396-405
   PubMed Web of Science ®Google Scholar
• Morgan TR, Ghany MG, Kim HY, et al. HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52(3):833-44
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21):1-113
   Web of Science ®Google Scholar
• Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132(1):103-12
   Google Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280(24):2088-93
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52(3):425-32
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Wasem J, et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ 2005;6(2):112-23
   PubMedGoogle Scholar
• Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009;27(4):341-54
   Google Scholar
• Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii-v.1-125
   PubMedGoogle Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11):1-205
   Web of Science ®Google Scholar
• Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon-alpha and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4:1-67
   PubMedGoogle Scholar
• Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011;14(8):1068-77
   PubMed Web of Science ®Google Scholar
• ISTAT 2010. Tavole di mortalità. Available from: http://dati.istat.it
   Google Scholar
• Ministero della Salute Decreto 18 ottobre 2012. Allegato 1. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale
   Google Scholar
• Munari L, Picciotto A. Recombinant interferon alfa-2b therapy ribavirin for initial treatment of chronic hepatitis C: a random- of chronic hepatitis C in Italy: an economic analysis. FORUM ised trial. Lancet 2001;358:958-65.Trends Exp Clin Med 1996;6:347-53
   PubMedGoogle Scholar
• Cicchetti A, Ruggeri M, Coretti S, et al. Valutazione economica di un programma di screening anti-HCV in Italia. PharmacoEconomics Italian Research Articles 2011;13(Suppl 2):pp 81-99
   Google Scholar
• AIFA, Eltrombopag (Eltrombopag) (Determina del 2-2-2011 - 43 del 22-02-2011)
   Google Scholar
• AIFA, Peginterferon alfa-2a (Pegasys) (Determina/C 2753/2011- GU n. 285 del 7-12-2011)
   Google Scholar
• OECD 2011. Available from: http://stats.oecd.org/
   Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11):1-205
   Web of Science ®Google Scholar
• Tariffa unica convenzionale (TUC); 2009
   Google Scholar
• Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15(17):i-xii.1-210
   PubMed Web of Science ®Google Scholar
• Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology 2011;53(6):1789-91
   PubMed Web of Science ®Google Scholar
• Sacchini D, Craxì L, Refolo P, et al. Ethical assessment of Hepatitis C virus treatment: the lesson of the first generation protease inhibitors. Dig Liver Dis 2014
   Google Scholar